Groupama Asset Managment Sells 4,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Groupama Asset Managment reduced its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 400,000 shares of the biotechnology company's stock after selling 4,000 shares during the quarter. Groupama Asset Managment owned approximately 0.66% of Ascendis Pharma A/S worth $55,068,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Trexquant Investment LP boosted its position in Ascendis Pharma A/S by 235.9% during the fourth quarter. Trexquant Investment LP now owns 27,067 shares of the biotechnology company's stock valued at $3,726,000 after acquiring an additional 19,010 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Ascendis Pharma A/S by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 57,077 shares of the biotechnology company's stock valued at $7,858,000 after purchasing an additional 629 shares in the last quarter. Schroder Investment Management Group grew its stake in Ascendis Pharma A/S by 14.5% during the fourth quarter. Schroder Investment Management Group now owns 92,728 shares of the biotechnology company's stock worth $12,656,000 after purchasing an additional 11,739 shares during the period. Nomura Asset Management Co. Ltd. increased its holdings in Ascendis Pharma A/S by 13.9% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 20,506 shares of the biotechnology company's stock worth $2,823,000 after purchasing an additional 2,506 shares in the last quarter. Finally, New Age Alpha Advisors LLC acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $507,000.

Remove Ads

Ascendis Pharma A/S Price Performance

Shares of ASND stock traded down $7.42 on Friday, hitting $142.67. The stock had a trading volume of 576,851 shares, compared to its average volume of 471,865. The business has a 50 day moving average of $146.39 and a 200 day moving average of $138.01. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37. The stock has a market cap of $8.66 billion, a price-to-earnings ratio of -20.09 and a beta of 0.61.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on ASND shares. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. UBS Group started coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price for the company. Cantor Fitzgerald upped their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 25th. Finally, The Goldman Sachs Group raised their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $204.64.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.